Over the years, extensive R&D efforts have
enabled microbiome-based therapy / diagnostic developers to make significant
strides, in terms of progressing p
Over the years, extensive R&D efforts have
established the basis for a wide range of microbiome-based therapeutic and diagnostic
products, which may cause
To order this 300+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.htmlKey Inclusions§ A deta
Several
big pharma companies are known to outsource more than half of their clinical-stage
oligonucleotide manufacturing operations. Anticipating a sharp rise
Roots Analysis has done a detailed
study on “Oligonucleotide
Synthesis, Modification and Purification Services Market: Focus on
Research, Diagnostic and Ther
The applications of
oligonucleotides are vast, even beyond the life science / pharma sector;
however, owing to complexities associated with the synthesis and
To order this detailed 300+ page report, please visit this -
https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.ht
Development
initiatives of HPAPIs and cytotoxic drugs are generally very demanding, both in
terms of experience and capital investment. Most companies general
Roots Analysis has done a detailed study on “HPAPI
and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030”, covering key aspects of the industry’s evolution
Manufacturing highly potent drug products is technically and financially
demanding; as a result, drug manufacturers are becoming increasingly reliant on
contr
To order this 550+ page report, please visit
this - https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.htmlKey Inclusions§
A d
Owing to various reasons, the demand for cell therapies is
anticipated to increase over the coming years. Therefore, both therapy developers
and contract serv
Roots Analysis has done a detailed study on Cell Therapy Manufacturing Market (3rd Edition),
2019 - 2030”, covering various important aspects of the industry a
Manufacturing cell therapies is technically and financially
demanding; as a result, despite therapy developers gradually strengthening
their in-house expertis
The approval of KYMIRAH®, YESCARTA®, Alofisel® and
Zyntelgo® has increased the interest of pharma stakeholders in cell therapies;
further, owing to the techni